Physician profile
Paul W Decker
NPI 1316033707
$2,765.91
in general payments reported to CMS, 2019-2025
32 companies · $841 in 2025
The $841 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2021: $38.65 · 2022: $327 · 2023: $556 · 2024: $844 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $407.25 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $245.13 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.67 | 2022-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $188.94 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $188.01 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $187.47 | 2022-2024 | Ubrelvy, Vraylar |
| Kowa Pharmaceuticals America, INC. | $174.45 | 2019-2024 | Livalo, Zoryve |
| Inspire Medical Systems, INC. | $111.31 | 2024-2025 | Inspire |
| Sanofi Pasteur INC. | $110.68 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $102.15 | 2021-2024 | Nuedexta |
| Pfizer INC. | $100.95 | 2023-2025 | |
| Novo Nordisk INC | $82.48 | 2024-2025 | Ozempic, Wegovy |
| Seqirus USA INC | $66.41 | 2024-2025 | Fluad, Flucelvax |
| Antares Pharma, INC. | $61.48 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $56.06 | 2023-2025 | Eterna, Freestyle Libre 3, Octrode |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $51.14 | 2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $48.46 | 2025 | |
| Avanir Pharmaceuticals, INC. | $46.97 | 2022 | |
| Merck Sharp & Dohme LLC | $43.80 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Allergan, INC. | $31.50 | 2019 | |
| Boston Scientific Corporation | $30.13 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.84 | 2022 | |
| Idorsia Pharmaceuticals US INC | $24.55 | 2022 | |
| Corium, LLC | $21.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.04 | 2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $18.75 | 2025 | Voquezna |
| Upsher-Smith Laboratories LLC | $18.73 | 2022 | |
| Esperion Therapeutics, INC. | $17.35 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $16.66 | 2025 | Contrave |
| Tolmar, INC. | $15.93 | 2025 | Jatenzo |
| Cranial Technologies, INC | $14.18 | 2023 | Doc Band |
| Sunovion Pharmaceuticals INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.